Prema Peethambaram, MD

Prema Peethambaram, MD, Associate Professor

Oncology Rochester, MN

COnsultant and Associate Professor Mayo College of Medicine

Office Address

  • 200 1st St Sw
    Rochester, MN 55905
    Phone: (507) 284-2511

Prema Peethambaram, MD, Associate Professor

Oncology Rochester, MN

COnsultant and Associate Professor Mayo College of Medicine

Clinical Specialties & Interests

  • Breast Cancer
  • Clinical Interests: Therapeutics

Education & Training

  • Mayo School of Graduate Medical EducationMayo School of Graduate Medical Education
  • Henry Ford Hospital - Wayne State UniversityHenry Ford Hospital - Wayne State University
  • Stanley Medical College SMCStanley Medical College SMC

Certifications & Licensure

  • MN State Medical LicenseMN State Medical License1994 - 2016
  • American Board of Internal MedicineMedical Oncology

    Awards, Honors, & Recognition

    • Travel Award for PosterAmerican Society of Clinical Oncology, 1995
    • Outstanding Teacher of the YearHenry Ford Hospital, 1993-1994
    • Intern of the Month AwardHenry Ford Hospital, 1991

    Publications & Presentations


    Journal Articles

    • Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer  AlHilli MM, Mariani A, Bakkum-Gamez JN, Dowdy SC, Weaver AL, Peethambaram PP, Keeney GL, Cliby WA, Podratz KC, Gynecol Oncol, 6/1/2014
    • Soyfood consumption in breast cancer survivors: Don't overstate the facts!  Peethambaram P, Olson J, Loprinzi CL, Oncology, 1/1/2013
    • Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment  Coleman S, Peethambaram PP, Jatoi A, J Cancer Educ, 9/1/2011

    Books/Book Chapters

    • Supportive Care in Cancer: A Handbook for Oncologists Chapter: Management of cancer anorexia and cachexia. Page 297 - 308
      Peethambaram PP, Loprinzi CL
      Editors: Klastersky J, et al.Marcel Dekker, Inc., New York, NY
      Edition 2nd,1999
    • Principles and Practice of Supportive Oncology Chapter: Cancer anorexia/cachexia. Page 133 - 139
      Loprinzi CL, Goldberg RM, Peethambaram PP
      Editors: Berger A, et al.Lippincott-Raven Publishers, Philadelphia


    • Phase i dose-escalation and drug interaction study of abt-888 (parp1 inhibitor) and topotecan (topoisomerase I inhibitor) in patients with advanced cancer. Boakye-Agyeman F, Reid J, Menefee M, Buhrow S, Walden C, Piens J, Kayode O, Erlichman C, Haluska P, Northfelt DW, Kaufmann SH, Ames M, Satele DV, Tang H, Peethambaram ..., Clin Pharmacol Ther, 3/1/2014
    • Results from two phase 1 trials of HER2/NEU-directed active cellular immunotherapy in patients with advanced malignancies. Sims RB, Park JW, Peethambaram PP, Melisko M, Rinn KJ, Alberts SR, Provost NM, Ann Oncol, 10/1/2010
    • Phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Haluska P, Oberg AL, Dakhil SR, Ziegler KLA, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP, Ann Oncol, 5/1/2009


    • Androgens and anti-androgens to treat breast cancer. Rochester, MN - 3/1/2013
    • The "pain" truth about aromatase inhibitors. Rochester, MN - 5/1/2012
    • "Journal club" Rochester, MN - 8/1/2011

    Professional Memberships

    Hospital Affiliations

    • The full profile is locked and available to verified physicians only.
      Join over 60% of U.S. physicians already on Doximity and get access to this and over 700,000 physician CVs. Find your physician profile

    Physicians, view Dr. Peethambaram's full Doximity profile to:

    • Trade HIPAA-secure messages
    • Send and receive online faxes
    • Refer a patient
    • See their complete CV